Naibec Obtains European Patent for Peptide-Based Implant Core Technology

Naivek announced on the 2nd that its self-developed patent for 'peptide technology with titanium bonding ability' has been registered in Europe. Following the export of bone regeneration materials for implants, this patent registration is expected to further accelerate Naivek's penetration into the European implant market.

The patented technology focuses on effectively bonding bioactive substances to titanium, a key material for implants, thereby enhancing surgical success rates and safety. Specifically, peptides containing functional drugs are specifically bonded to the surface of titanium implants. Through these functional drugs, the implants promote the formation of new bone tissue during the initial implantation phase as well as adhesion with the surrounding bone, increasing the stability of the implant.

Naivek's patent is particularly useful for elderly patients and those with chronic periodontal disease. Previously, it was difficult to administer active substances such as bone morphogenetic proteins simultaneously with implant placement in patients with low bone density or deteriorated bone quality. Since the patented technology fixes bioactive substances onto the implant surface during implantation, it can significantly increase the success rate of implants.

Naivek also holds a patent for peptide technology applicable not only to titanium implants but also to 'zirconia' implants. Zirconia is a material that has recently gained attention in the implant market. According to the company, Naivek's peptide technology has broad compatibility applicable to both key implant materials, allowing customized solutions for patients during surgery.

A Naivek representative stated, "The registration of this European patent signifies the establishment of a global entry barrier for core peptide technology related to implants," adding, "In particular, Naivek's peptide technology is widely applicable to various key implant materials such as titanium and zirconia, attracting significant interest from global implant companies."

He continued, "Europe is a major export region for Naivek's bone regeneration materials for implants, with steadily increasing sales," and added, "Following the export of bone regeneration biomaterials, the acquisition of this core peptide technology patent for implants is expected to increase sales through synergy in the European implant market."